Altshuler Shaham’s Abeona Therapeutics ABEO Stock Holding History

Altshuler Shaham’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-4,778	Closed	-$879K	–	357
2019 Q1	$879K	Sell	4,778 -294	-6%	-$52.6K	0.04%	88
2018 Q4	$905K	Buy	5,072 +2,524	+99%	+$550K	0.04%	87
2018 Q3	$815K	Hold	2,548	–	–	0.04%	94
2018 Q2	$1.02M	Buy	2,548 +1,068	+72%	+$467K	0.08%	83
2018 Q1	$531K	Buy	+1,480	New	+$550K	0.07%	95

Other funds holding ABEO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Altshuler Shaham's ABEO Position: Q2 2019 in Review

Altshuler Shaham sold out of Abeona Therapeutics (ABEO) in Q2 2019, closing a stake of 4,778 shares — an estimated $879K sold.

Altshuler Shaham first reported a position in ABEO in Q1 2018 and held it in 5 quarters. The position peaked at $1.02M in Q2 2018. 98 funds tracked by Wall St. Rank hold ABEO as of Q2 2019.

Altshuler Shaham reported no remaining Abeona Therapeutics position as of Q2 2019 after selling out during the quarter.
Altshuler Shaham sold 4,778 Abeona Therapeutics shares in Q2 2019, an estimated $879K.
Altshuler Shaham first reported a position in Abeona Therapeutics in Q1 2018 and held it in 5 quarters.
Altshuler Shaham's Abeona Therapeutics position peaked at $1.02M in Q2 2018.
98 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2019.

Based on Altshuler Shaham's 13F filing for Q2 2019, filed 6 Aug 2019.